Rapport Therapeutics, Inc. cotiza a 30.15 USD y tiene una capitalización bursátil de $1.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219,…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.19 | $-0.42 | $-0.72 |
| Estimado | $-1.23 | $-0.99 | $-0.71 | $-0.67 |
| Sorpresa | — | -20.2% | +40.8% | -7.5% |
| Métrica | RAPP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -23.0% | -40.4% | +17.4% |
| ROA | -21.8% | -32.0% | +10.2% |
| Current Ratio | 26.17 | 2.84 | +23.33 |
| Debt / Equity | — | 0.28 | — |